EGFR and adenocarcinoma in situ: We attribute this difference to the inclusion in our cohort of a number of patients who had tumours of the adenocarcinoma in situ (AIS) subtype (29.7%), in which the frequency of EGFR mutations was reported to be 27.3% or 23.8% [22, 23].